Your browser doesn't support javascript.
loading
SEOM clinical guideline of diagnosis and management of low-grade glioma (2017).
Sepúlveda-Sánchez, J M; Muñoz Langa, J; Arráez, M Á; Fuster, J; Hernández Laín, A; Reynés, G; Rodríguez González, V; Vicente, E; Vidal Denis, M; Gallego, Ó.
Afiliação
  • Sepúlveda-Sánchez JM; Neurooncology Unit, Hospital Universitario, 12 de Octubre, Madrid, Spain. juanmanuel.sepulveda@salud.madrid.org.
  • Muñoz Langa J; Medical Oncology Department, Hospital Universitari I Politècnic la Fe, Valencia, Spain.
  • Arráez MÁ; Neurosurgery Department, HRU Carlos Haya, Málaga, Spain.
  • Fuster J; Medical Oncology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
  • Hernández Laín A; Neuropathology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain.
  • Reynés G; Medical Oncology Department, Hospital Universitari I Politècnic la Fe, Valencia, Spain.
  • Rodríguez González V; Radiation Oncology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain.
  • Vicente E; Medical Oncology Department, C.H.U. Insular-Materno Infantil de Gran Canaria, Las Palmas, Spain.
  • Vidal Denis M; Neuroradiology Unit, HRU Carlos Haya, Málaga, Spain.
  • Gallego Ó; Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
Clin Transl Oncol ; 20(1): 3-15, 2018 Jan.
Article em En | MEDLINE | ID: mdl-29124520
ABSTRACT
Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas, and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed. The 2016 World Health Organization (WHO) classification has updated the definition of these tumors to include their molecular characterization, including the presence of isocitrate dehydrogenase (IDH) mutation and 1p/19p codeletion. In this new classification, the histologic subtype of grade II-mixed oligoastrocytoma has also been eliminated. The precise optimal management of patients with low-grade glioma after resection remains to be determined. The risk-benefit ratio of adjuvant treatment must be weighed for each individual.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioma Tipo de estudo: Diagnostic_studies / Guideline Limite: Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioma Tipo de estudo: Diagnostic_studies / Guideline Limite: Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha